832-497-2220 info@mybiogate.com

Pitch & Match provides an intimate venue for companies to quickly connect to China’s leading healthcare companies and investors, regarded as the most efficient way to maximize the success rate of fundraising and finding partners. 

Only through Pitch & Match, we provide our investors and presenting companies the opportunity to know each other before event day, get engaged through the presentation, Q&A and arrange immediate follow-up meetings.

Apply now and enjoy the limited time discount! We provide the first 5 applicants €500off on presenting at China Focus@Europe Hamburg or $500 off on China Focus@San FranciscoPromo Code: 500OFF

Featured Audiences (Previous Events)

Jiangsu Hengrui Medicine: a leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017, established in 1970. Hengrui is devoted to empowering healthier lives through research, with a team of over 20,000 employees in China, the United States, Australia, Japan, and Germany. Hengrui currently has 4 China NMPA approved new molecular entities, as well as over 35 new molecular entities in clinical development in China, the United States, and Australia, across oncology, anesthesiology and pain management, immunology & inflammation, and cardiovascular and metabolic diseases.
President of Global R&D;
US Head of Global Business Development;
Director and China Head of Business Development;
Director of Global Business Development

Fosun Pharma: Fosun Pharma regards innovation, research, and development as the core driving factor of development and established innovative chemical drugs platform, biologics platform, high-value generic drugs platform, and cell-therapy platform. Currently, Fosun Pharma continues to focus on therapeutic areas including oncology, cardiovascular system, central nervous system, blood system, metabolism, and alimentary system and anti-infection.
Fosun US CEO
Senior Advisor
Chief Scientific Officer

Sequoia Capital China: Sequoia Capital China invests between $100,000 and $1 million in seed companies, between $1 million and $10 million in the early venture, and between $10 million and $50 million in growth investments. Sequoia Capital China was founded in September 2005 and is based in Beijing, China with additional offices in Admiralty, Hong Kong, and Shanghai, China. Sequoia Capital China operates as a subsidiary of Sequoia Capital. It invests in the healthcare sector across medical treatment services, mobile healthcare, innovative medicine, generic and new medicine, diagnostic services, genetics services, lab services, medical treatment equipment and facilities, patient services, doctor-patient platforms, vertical medical consultation start-ups, product development services and enabling technology companies.
Managing Director

Morningside Group: Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.
Managing Director

Download Complete Audience List

Date: Jan 12, 2020

Location: Grand Hyatt San Francisco
345 Stockton St
San Francisco, CA, U.S.

Apply Now

Date: Nov 10, 2019

Location: Grand Elysée Hamburg
Rothenbaumchaussee 10
20148 Hamburg, Germany

Apply Now


The audience list of in Hamburg and San Francisco events will be released soon, please stay tuned!